EMAIL THIS PAGE TO A FRIEND

Expert opinion on investigational drugs

Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?


PMID 11996652

Abstract

Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may be the immunomodulatory effect that underlies its ability to reduce atherosclerosis. N,N-Diacetyl-L-cystine is not an antioxidant but is immunomodulatory. In the Watanabe-heritable hyperlipidaemic rabbit model of familial hypercholesterolaemia, N,N-diacetyl-L-cystine treatment does not lower lipid levels but it does reduce atherosclerosis. Immunomodulation may be a new approach to the treatment of atherosclerosis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A0152000 Acetylcysteine impurity C, European Pharmacopoeia (EP) Reference Standard
C10H16N2O6S2